Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor

Journal of Medicinal Chemistry

Volumn 53, Issue 7, 2010, Pages 2892-2901

  Pawar, Vijaykumar G ^a   Sos, Martin L ^b   Rode, Haridas B ^a   Rabiller, Matthias ^a   Heynck, Stefanie ^b   Van Otterlo, Willem A L ^a,c   Thomas, Roman K ^a,b   Rauh, Daniel ^a  

^a CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; N (3 ETHYNYLPHENYL) 6,7 BIS(2 METHOXYETHOXY)QUINOLIN 4 AMINE; N (3 ETHYNYLPHENYL) 6,7 DIMETHOXYQUINAZOLIN 4 AMINE; N (3 ETHYNYLPHENYL) 6,7 DIMETHOXYQUINOLIN 4 AMINE; N [4 (3 BROMOPHENYLAMINO)QUINAZOLINE 6 YL]ACRYLAMIDE; N [4 (3 BROMOPHENYLAMINO)QUINAZOLINE 6 YL]PROPIONAMIDE; N [4 (3 BROMOPHENYLAMINO)QUINOLIN 6 YL] 4 (DIMETHYLAMINO)BUTANAMIDE; N [4 (3 BROMOPHENYLAMINO)QUINOLIN 6 YL]ACRYLAMIDE; N [4 (3 BROMOPHENYLAMINO)QUINOLIN 6 YL]PROPIONAMIDE; N [4 [(3 BROMO PHENYL)AMINO]QUINAZOLINE 6 YL]4 (DIMETHYLAMINO)BUTANAMIDE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; LUNG SMALL CELL CANCER; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950589013     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901877j     Document Type: Article

References (26)

1. Sharma, S. V.; Bell, D. W.; Settleman, J.; Haber, D. A. Epidermal growth factor receptor mutations in lung cancer Nat. Rev. Cancer 2007, 7, 169 - 181
2. Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Müller, G. Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition Expert Opin. Drug Discovery 2008, 3, 1409 - 1425
3. Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Müller, G. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition Expert Opin. Drug Discovery 2008, 3, 1427 - 1449
4. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; Singh, B.; Heelan, R.; Rusch, V.; Fulton, L.; Mardis, E.; Kupfer, D.; Wilson, R.; Kris, M.; Varmus, H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 13306 - 13311
5. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H. R.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor J. Med. Chem. 1995, 38, 3482 - 3487
6. Wissner, A.; Berger, D. M.; Boschelli, D. H.; Floyd, M. B.; Greenberger, L. M.; Gruber, B. C.; Johnson, B. D.; Mamuya, N.; Nilakantan, R.; Reich, M. F.; Shen, R.; Tsou, H. R.; Upeslacis, E.; Wang, Y. F.; Wu, B. Q.; Ye, F.; Zhang, N. 4-Anilino-6,7-dialkoxyquinolime-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors J. Med. Chem. 2000, 43, 3244 - 3256
7. Wissner, A.; Mansour, T. S. The development of HKI-272 and related compounds for the treatment of cancer Arch. Pharm. 2008, 341, 465 - 477
8. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 2002, 277, 46265 - 46272
9. Hennequin, L. F.; Allen, J.; Breed, J.; Curwen, J.; Fennell, M.; Green, T. P.; Lambert-van der Brempt, C.; Morgentin, R.; Norman, R. A.; Olivier, A.; Otterbein, L.; Ple, P. A.; Warin, N.; Costello, G. N -(5-Chloro-1,3-benzodioxol- 4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2 H -pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor J. Med. Chem. 2006, 49, 6465 - 6488
10. Rachid, Z.; Brahimi, F.; Qiu, Q.; Williams, C.; Hartley, J. M.; Hartley, J. A.; Jean-Claude, B. J. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: Discovery of an unusual structure-activity relationship J. Med. Chem. 2007, 50, 2605 - 2608
11. Wissner, A.; Fraser, H. L.; Ingalls, C. L.; Dushin, R. G.; Floyd, M. B.; Cheung, K.; Nittoli, T.; Ravi, M. R.; Tan, X. Z.; Loganzo, F. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2 Bioorg. Med. Chem. 2007, 15, 3635 - 3648
12. Michalczyk, A.; Klüter, S.; Rode, H. B.; Simard, J. R.; Grütter, C.; Rabiller, M.; Rauh, D. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR Bioorg. Med. Chem. 2008, 16, 3482 - 3488
13. Carter, T. A.; Wodicka, L. M.; Shah, N. P.; Velasco, A. M.; Fabian, M. A.; Treiber, D. K.; Milanov, Z. V.; Atteridge, C. E.; Biggs, W. H., 3rd; Edeen, P. T.; Floyd, M.; Ford, J. M.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Mehta, S. A.; Patel, H. K.; Pao, W.; Sawyers, C. L.; Varmus, H.; Zarrinkar, P. P.; Lockhart, D. J. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Proc. Natl. Acad. Sci. U.S.A 2005, 102, 11011 - 11016
14. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2005, 2, 225 - 235
15. Yun, C. H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich, H.; Wong, K. K.; Meyerson, M.; Eck, M. J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U.S.A 2008, 105, 2070 - 2075
16. Getlik, M.; Grütter, C.; Simard, J. R.; Klüter, S.; Rabiller, M.; Rode, H. B.; Robubi, A.; Rauh, D. Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc J. Med. Chem. 2009, 52, 3915 - 3926
17. Sos, M. L.; Rode, H. B.; Heynck, S.; Peifer, M.; Fischer, F.; Klüter, S.; Pawar, V.; Reuter, C.; Heuckmann, J. M.; Weiss, J.; Ruddigkeit, L.; Rabiller, M.; Koker, M.; Simard, J. R.; Getlik, M.; Yuza, Y.; Chen, J. Y.; Greulich, H.; Thomas, R. K.; Rauh, D. Insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation from chemo-genomics profiling Cancer Res. 2010, 70, 859 - 862
18. Hennequin, L. F.; Thomas, A. P.; Johnstone, C.; Stokes, E. S. E.; Ple, P. A.; Lohmann, J. J. M.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Curwen, J. O.; Kendrew, J.; Lambert-van der Brempt, C. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors J. Med. Chem. 1999, 42, 5369 - 5389
19. Furuta, T.; Sakai, T.; Senga, T.; Osawa, T.; Kubo, K.; Shimizu, T.; Suzuki, R.; Yoshino, T.; Endo, M.; Miwa, A. Identification of potent and selective inhibitors of PDGF receptor autophosphorylation J. Med. Chem. 2006, 49, 2186 - 2192
20. Klüter, S.; Grütter, C.; Naquvi, T.; Rabiller, M.; Simard, J. R.; Pawar, V.; Getlik, M.; Rauh, D. Design of a displacement assay for kinases based on a DFG-out binding probe J. Med. Chem. 2009, 53, 357 - 367
21. Harmange, J.-C.; Weiss, M. M.; Germain, J.; Polverino, A. J.; Borg, G.; Bready, J.; Chen, D.; Choquette, D.; Coxon, A.; DeMelfi, T.; DiPietro, L.; Doerr, N.; Estrada, J.; Flynn, J.; Graceffa, R. F.; Harriman, S. P.; Kaufman, S.; La, D. S.; Long, A.; Martin, M. W.; Neervannan, S.; Patel, V. F.; Potashman, M.; Regal, K.; Roveto, P. M.; Schrag, M. L.; Starnes, C.; Tasker, A.; Teffera, Y.; Wang, L.; White, R. D.; Whittington, D. A.; Zanon, R. Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation J. Med. Chem. 2008, 51, 1649 - 1667 (Pubitemid 351438848)
22. Bridges, A. J.; Denny, W. A.; Dobrusin, E. M.; Doherty, A. M.; Fry, D. W.; McNamara, D. J.; Showalter, H. D. H.; Smaill, J. B.; Zhou, H. et al. Preparation of N -quinazolinylacrylamides and analogs as tyrosine kinase inhibitors. U.S. Patent 97-US5778 9738983, 19970408, 1997.
23. Sos, M. L.; Michel, K.; Zander, T.; Weiss, J.; Frommolt, P.; Peifer, M.; Li, D.; Ullrich, R.; Koker, M.; Fischer, F.; Shimamura, T.; Rauh, D.; Mermel, C.; Fischer, S.; Stuckrath, I.; Heynck, S.; Beroukhim, R.; Lin, W.; Winckler, W.; Shah, K.; LaFramboise, T.; Moriarty, W. F.; Hanna, M.; Tolosi, L.; Rahnenfuhrer, J.; Verhaak, R.; Chiang, D.; Getz, G.; Hellmich, M.; Wolf, J.; Girard, L.; Peyton, M.; Weir, B. A.; Chen, T. H.; Greulich, H.; Barretina, J.; Shapiro, G. I.; Garraway, L. A.; Gazdar, A. F.; Minna, J. D.; Meyerson, M.; Wong, K. K.; Thomas, R. K. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions J. Clin. Invest. 2009, 119, 1727 - 1740
24. Yuza, Y.; Glatt, K. A.; Jiang, J. R.; Greulich, H.; Minami, Y.; Woo, M. S.; Shimamura, T.; Shapiro, G.; Lee, J. C.; Ji, H. B.; Feng, W.; Chen, T. H.; Yanagisawa, H.; Wong, K. K.; Meyerson, M. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors Cancer Biol. Ther. 2007, 6, 661 - 667
25. Sos, M. L.; Koker, M.; Weir, B. A.; Heynck, S.; Rabinovsky, R.; Zander, T.; Seeger, J. M.; Weiss, J.; Fischer, F.; Frommolt, P.; Michel, K.; Peifer, M.; Mermel, C.; Girard, L.; Peyton, M.; Gazdar, A. F.; Minna, J. D.; Garraway, L. A.; Kashkar, H.; Pao, W.; Meyerson, M.; Thomas, R. K. PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR Cancer Res. 2009, 69, 3256 - 3261
26. Blair, J. A.; Rauh, D.; Kung, C.; Yun, C. H.; Fan, Q. W.; Rode, H.; Zhang, C.; Eck, M. J.; Weiss, W. A.; Shokat, K. M. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics Nat. Chem. Biol. 2007, 3, 229 - 238